Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 14/20 | 0.52 |
| ▸ | SCN2B | O60939 | 9/20 | 0.52 |
| ▸ | SCN1B | Q07699 | 9/20 | 0.52 |
| ▸ | SCN5A | Q14524 | 8/20 | 0.52 |
| ▸ | SCN1A | P35498 | 7/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12089439 | 0.82 | SCN9A (0.50) | SCN9ASCN2BSCN1BSCN5ASCN1A | |
| SCHEMBL12089433 | 0.76 | HTR2A (0.38) | SCN9AHTR7 | |
| SCHEMBL17171608 | 0.71 | SCN9A (0.38) | SCN9ASCN2BSCN1BSCN5ASCN1A | |
| SCHEMBL7987812 | 0.69 | SCN9A (0.55) | SCN9ASCN2BSCN1BSCN5ASCN1A | |
| SCHEMBL12090043 | 0.68 | NAMPT (0.49) | — | |
| SCHEMBL12089746 | 0.66 | NOTUM (0.55) | MYC | |
| SCHEMBL17171603 | 0.65 | NOTUM (0.41) | — | |
| SCHEMBL10325103 | 0.62 | MAOB (0.57) | SCN9ASCN2BSCN1BSCN5ASCN1A | |
| SCHEMBL27871304 | 0.62 | ALDH1A1 (0.49) | — | |
| SCHEMBL703171 | 0.62 | BCL2L1 (0.59) | SCN9ASCN2BSCN1BSCN5ASCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9675584-B2 | Substituted indoles for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2017-06-13 | — | — | US | disclosed |
| US-9675584-B2 | Substituted indoles for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2017-06-13 | — | — | US | disclosed |
| US-20150290169-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX, LLC | 2015-10-15 | — | — | US | disclosed |
| US-20150290169-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX, LLC | 2015-10-15 | — | — | US | disclosed |
| US-9012637-B2 | Substituted pyrazinyl acrylic acid compounds for the inhibition of pask | BIOENERGENIX, LLC (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012637-B2 | Substituted pyrazinyl acrylic acid compounds for the inhibition of pask | BIOENERGENIX, LLC (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140235579-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX, LLC | 2014-08-21 | — | — | US | disclosed |
| US-20140235579-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX, LLC | 2014-08-21 | — | — | US | disclosed |
| US-20120225846-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225846-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225846-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | SCN9A 3929/4885SCN2B 4071/4885SCN1B 3079/4885 |
| US-20140235579-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | SCN9A 3929/4885SCN2B 4071/4885SCN1B 3079/4885 |
| US-20150290169-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | SCN9A 3929/4885SCN2B 4071/4885SCN1B 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.